Tracking B cell responses to the SARS-CoV-2 mRNA-1273 vaccine.

Publication date: Jul 12, 2023

Protective immunity following vaccination is sustained by long-lived antibody-secreting cells and resting memory B cells (MBCs). Responses to two-dose SARS-CoV-2 mRNA-1273 vaccination are evaluated longitudinally by multimodal single-cell analysis in three infection-nacEFve individuals. Integrated surface protein, transcriptomics, and B cell receptor (BCR) repertoire analysis of sorted plasmablasts and spike (S-2P) and S-2P B cells reveal clonal expansion and accumulating mutations among S-2P cells. These cells are enriched in a cluster of immunoglobulin G-expressing MBCs and evolve along a bifurcated trajectory rooted in CXCR3 MBCs. One branch leads to CD11c atypical MBCs while the other develops from CD71 activated precursors to resting MBCs, the dominant population at month 6. Among 12 evolving S-2P clones, several are populated with plasmablasts at early timepoints as well as CD71 activated and resting MBCs at later timepoints, and display intra- and/or inter-cohort BCR convergence. These relationships suggest a coordinated and predictable evolution of SARS-CoV-2 vaccine-generated MBCs.

Open Access PDF

Concepts Keywords
Atypical B cells
Plasmablasts BCR repertoire
Transcriptomics CP: Immunology
Vaccination immunological memory
mRNA vaccine
single-cell profiling


Type Source Name
disease IDO cell
disease VO vaccine
disease VO vaccination
disease VO dose
disease MESH infection
disease VO population
disease MESH Allergy
disease MESH Infectious Diseases
disease VO USA
pathway REACTOME Immune System
disease MESH COVID 19
disease IDO host
disease IDO susceptibility
disease VO effectiveness
disease VO effective
drug DRUGBANK Hyaluronic acid
disease VO time
disease VO primary vaccination
disease VO vaccine dose
disease IDO blood
disease VO URE
disease MESH inflammation
disease VO gene
drug DRUGBANK Proline
disease VO frequency
disease IDO adaptive immune response
disease MESH mutation frequency
disease IDO history
disease IDO production
disease VO vaccine efficacy
drug DRUGBANK Methylergometrine
disease MESH convalescence
drug DRUGBANK Guanosine
disease MESH systemic lupus erythematosus
pathway KEGG Systemic lupus erythematosus
disease MESH Autoimmunity
disease MESH malaria
pathway KEGG Malaria
disease VO efficient
disease IDO immune response
disease MESH viral infection
disease MESH HIV infection
disease MESH influenza
disease VO vaccinated
disease MESH breakthrough infection
disease MESH Leukemia
drug DRUGBANK L-Leucine
disease MESH smallpox
disease MESH etiology
disease VO immunization
drug DRUGBANK Immune Globulin Human
drug DRUGBANK Biotin
drug DRUGBANK Chromium
drug DRUGBANK Coenzyme M
disease VO protocol
disease IDO site
drug DRUGBANK Phosphate ion
drug DRUGBANK Aspartame
drug DRUGBANK Methionine
disease IDO object
drug DRUGBANK Pidolic Acid
disease IDO algorithm
disease MESH premature stop codons
disease IDO process
disease MESH uncertainty

Original Article

(Visited 1 times, 1 visits today)

Leave a Comment

Your email address will not be published. Required fields are marked *